2025
Observational pilot using a Data to Care intervention strategy to promote HCV re-engagement and cure for persons with HIV/HCV co-infection who are out of care
Wegener M, Gosselin D, Brooks R, Speers S, Villanueva M. Observational pilot using a Data to Care intervention strategy to promote HCV re-engagement and cure for persons with HIV/HCV co-infection who are out of care. BMC Health Services Research 2025, 25: 140. PMID: 39856760, PMCID: PMC11763122, DOI: 10.1186/s12913-025-12307-6.Peer-Reviewed Original ResearchConceptsDepartment of Public HealthHepatitis C virus treatment initiationHIV/HCV co-infectionHepatitis C virusPublic health strategiesConnecticut Department of Public HealthRe-engagementMethodsIn partnershipOutreach outcomesCare engagementCo-infectionHealth strategiesTreatment initiationHIV/HCV co-infected personsHepatitis C virus cureFollow-up approachHepatitis C virus treatmentCo-infected personsDirect-acting antiviralsIntervention strategiesPublic healthOutreach effortsPersons co-infectedHIVObservational pilotFactors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.
Kim S, Can M, Agizew T, Auld A, Balcells M, Bjerrum S, Dheda K, Dorman S, Esmail A, Fielding K, Garcia-Basteiro A, Hanrahan C, Kebede W, Kohli M, Luetkemeyer A, Mita C, Reeve B, Silva D, Sweeney S, Theron G, Trajman A, Vassall A, Warren J, Yotebieng M, Cohen T, Menzies N. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis. PLOS Medicine 2025, 22: e1004502. PMID: 39804959, PMCID: PMC11729971, DOI: 10.1371/journal.pmed.1004502.Peer-Reviewed Original ResearchConceptsIndividual patient data meta-analysisPatient data meta-analysisTreatment initiationData meta-analysisBacteriological test resultsTB treatmentFactors associated with treatment initiationMultiple factors influence decisionsAssociated with treatment initiationTuberculosis treatment initiationMeta-analysisNegative test resultsPositive test resultsFactors influence decisionsHIV infectionPulmonary tuberculosisSmear microscopyNight sweatsClinical examinationMale sexClinical criteriaHierarchical Bayesian logistic regressionCohort studySystematic reviewTreatment decisionsAutogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, Balmanoukian A, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher G, Schmidt M, Schuler M, Sullivan R, Burris H, Galvao V, Henick B, Dirix L, Jaeger D, Ott P, Wong K, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner R, Rittmeyer A, Laurie S, Gort E, Aljumaily R, Melero I, Sabado R, Rhee I, Mancuso M, Muller L, Fine G, Yadav M, Kim L, Leveque V, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao G, Low D, Petry C, Lo A, Schartner J, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor A, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn A, Sahin U, Türeci Ö, Camidge D. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine 2025, 31: 152-164. PMID: 39762422, PMCID: PMC11750724, DOI: 10.1038/s41591-024-03334-7.Peer-Reviewed Original ResearchConceptsCD8+ T cellsAdvanced solid tumorsT cellsSolid tumorsCirculating CD8+ T cellsEfficacy of cancer immunotherapyTumor-infiltrating T cellsStimulate T cell responsesResponse to immunotherapyT cell responsesPreliminary antitumor activityPhase 1 studyPhase 1 trialDose escalationPretreated patientsCancer immunotherapyEvaluation of pharmacokineticsCD4+Tumor lesionsTreatment initiationTumor tissuesAtezolizumabClinical activityDisease characteristicsImmunotherapy
2024
Statistical Methods for Accommodating Immortal Time: A Selective Review and Comparison
Wang J, Peduzzi P, Wininger M, Ma S. Statistical Methods for Accommodating Immortal Time: A Selective Review and Comparison. 2024, 53-92. DOI: 10.1007/978-3-031-65937-9_3.Peer-Reviewed Original ResearchAcute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-trans retinoic acidDelayed diagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settingsReal-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Doshi J, Li P, Geng Z, Lei X, Pettit A, Armstrong K, Huntington S, Lin J. Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer. Blood 2024, 144: 786-786. DOI: 10.1182/blood-2024-203410.Peer-Reviewed Original ResearchInsurance typeBlood cancerMedicare patientsCommercial insuranceStep therapyFormulary coverageNationwide sample of patientsPrior authorizationTreatment plan changesDelayed treatment initiationMonths pre-indexOdds of rejectionLonger treatment durationLife-extending therapyReal-world studyOral anticancer medicationsSample of patientsBlood cancer patientsPatient ageClinical characteristicsTreatment initiationReal-world analysisBrand-nameRetrospective analysisPre-indexInequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy
Zeidan A, Xu Y, Kapustyan T, Miu K, Chen C, Kamalakar R, Lin C, Ma E, Montez M, Wu Z, Yee T, Sun H, Rava A, Kim S, Huntington S. Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy. Blood 2024, 144: 3795-3795. DOI: 10.1182/blood-2024-200213.Peer-Reviewed Original ResearchTime to treatment initiationND-AMLAssociated with lower oddsAcute myeloid leukemiaAML treatmentVEN-HMACharlson Comorbidity IndexTargeted therapyInduction therapyFemale patientsMyeloid leukemiaTreatment initiationShorter time to treatment initiationTherapy uptakeMedicare beneficiariesNewly diagnosed acute myeloid leukemiaLower oddsOdds ratioHematopoietic stem cell transplantationTime-to-treatment initiationDiagnosed acute myeloid leukemiaIn-hospital survival rateLow-dose chemotherapyClinical performance statusStem cell transplantationMDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial
Zeidan A, Platzbecker U, Della Porta M, Santini V, Garcia-Manero G, Li J, Kreitz S, Pozharskaya V, Rose S, Lai Y, Davidárcel D, Fenaux P, Shortt J, Komrokji R. MDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s387-s388. DOI: 10.1016/s2152-2650(24)01346-6.Peer-Reviewed Original ResearchEA patientsTransfusion-dependentRBC unitsLuspatercept treatmentRBC-TITransfusion burdenMyelodysplastic syndromeLR-MDSRBC transfusionIntermediate-risk myelodysplastic syndromesEA-treated patientsRBC transfusion independenceBone marrow blastsLowered riskTransfusion independenceMarrow blastsTreatment initiationCumulative medianLuspaterceptEpoetin alfaESA-naivePatients adultsEffective treatmentPatientsInterquartile rangeHealth-seeking behaviour and patient-related factors associated with the time to TB treatment initiation in four African countries: a cross-sectional survey
Sathar F, Charalambous S, Velen K, Fielding K, Rachow A, Ivanova O, Rassool M, Lalashowi J, Owolabi O, Nhassengo P, Chihota V, Evans D. Health-seeking behaviour and patient-related factors associated with the time to TB treatment initiation in four African countries: a cross-sectional survey. BMJ Public Health 2024, 2: e001002. PMID: 40018527, PMCID: PMC11816287, DOI: 10.1136/bmjph-2024-001002.Peer-Reviewed Original ResearchTB treatment initiationCross-sectional surveyTB symptomsPrimary care facilitiesTreatment initiationMedian total delayHealth-seeking behaviorNational TB Control ProgrammeTB treatmentCohort of adultsTB control programmesActive case findingPatient-related factorsHealth facilitiesTB servicesHIV prevalenceCare facilitiesDrug-susceptible pulmonary TBTotal delaySecond-leading causeTime to treatment initiationCase findingCox regression modelsStructured questionnaireInitiation of treatmentReal-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e350-e358.e1. PMID: 39034204, DOI: 10.1016/j.clml.2024.05.023.Peer-Reviewed Original ResearchR/R MCLOverall survivalTreatment patternsRelapsed/refractory mantle cell lymphomaReal-world treatment patternsBruton tyrosine kinase inhibitorCovalent Bruton tyrosine kinase inhibitorMantle cell lymphomaTyrosine kinase inhibitorsDevelopment of novel therapeuticsMCL patientsCell lymphomaThird-lineRetrospective studyTreatment initiationResponse durationAdverse eventsElderly patientsKinase inhibitorsPatient subpopulationsPatientsAll-causeNovel therapeuticsEconomic burdenSurvivalEnhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With Human Immunodeficiency Virus Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial
Burke R, Nyirenda S, Mtenga T, Twabi H, Joekes E, Walker N, Nyirenda R, Gupta-Wright A, Nliwasa M, Fielding K, MacPherson P, Corbett E. Enhanced Tuberculosis Diagnosis With Computer-aided Chest X-ray and Urine Lipoarabinomannan in Adults With Human Immunodeficiency Virus Admitted to Hospital (CASTLE Study): A Cluster Randomized Trial. Clinical Infectious Diseases 2024, ciae273. PMID: 38748183, DOI: 10.1093/cid/ciae273.Peer-Reviewed Original ResearchCluster randomised trialTB treatment initiationUsual careChest X-rayPlus usual careUsual care armRandomised trialsTB diagnosisUrine lipoarabinomannanAntiretroviral therapyTreatment initiationDiagnostic armZomba Central HospitalIntention-to-treat analysisTB diagnosticsAdmitted to hospitalModified intention-to-treat analysisCare armCD4 cell countDigital chest X-rayUndiagnosed TBPost-recruitmentCause of deathSecondary outcomesPrimary outcomePredicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices
Giuffrè M, Dupont J, Visintin A, Masutti F, Monica F, You K, Shung D, Crocè L. Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices. Hepatology International 2024, 1-12. PMID: 38664292, DOI: 10.1007/s12072-024-10649-7.Peer-Reviewed Original ResearchHigh-risk varicesHepatic venous pressure gradientLiver stiffnessLiver cirrhosisSpleen stiffnessVariceal gradeHeart rateCohort of cirrhotic patientsNon-selective beta-blockersPercentual decreaseAssessed therapeutic responseMultivariate modelVenous pressure gradientCut-off valueOptimal cut-offAssociated with better predictionNSBB treatmentPrimary prophylaxisHemorrhagic episodesCirrhotic patientsTherapeutic responseBeta-blockersNSBBTreatment initiationProspective studySecond‐line immunotherapy in new onset refractory status epilepticus
Hanin A, Muscal E, Hirsch L. Second‐line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024, 65: 1203-1223. PMID: 38430119, DOI: 10.1111/epi.17933.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeSecond-line immunotherapyOnset refractory status epilepticusRefractory status epilepticusIntrathecal dexamethasoneStatus epilepticusCytokine levelsFunctional outcomesCerebrospinal fluid cytokine levelsInitiation of anakinraReduction of seizure frequencyLong-term functional outcomeResponse to treatmentSE onsetElevated serumFebrile infectionsImmune dysregulationLong-term disabilityTreatment initiationCase reportCytokine measurementsProspective studyAnakinraImmunotherapyTocilizumabClinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States
Lembo A, Cash B, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M. Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States. Clinical And Translational Gastroenterology 2024, 15: e00687. PMID: 38357940, DOI: 10.14309/ctg.0000000000000687.Peer-Reviewed Original ResearchConstipation-related symptomsChronic idiopathic constipationProportion of patientsComplications 6 monthsIdiopathic constipationRetrospective cohort analysisDecreased 6 monthsMedicare Supplemental databaseICD-10 procedurePatient ageTreatment initiationClinical outcomesPrucalopride treatmentCohort analysisComplicationsPrucaloprideObservational studyPatientsSupplemental databaseICD-10 Procedure Coding SystemCommercial ClaimsDiagnosis codesICD-10-CMSymptomsClinical Modification
2023
A Phase 2a proof‐of‐concept double‐blind, randomized, placebo‐controlled trial of nicotinamide in early Alzheimer’s disease
Grill J, Tam S, Thai G, Pierce A, Green K, Gillen D, Teng E, Kremen S, Beigi M, Rissman R, Leger G, Zhang J, Jin S, Messer K, Feldman H. A Phase 2a proof‐of‐concept double‐blind, randomized, placebo‐controlled trial of nicotinamide in early Alzheimer’s disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077979.Peer-Reviewed Original ResearchPhase 2a proofP-Tau 181Placebo armTotal tauCDR-SBEarly ADAmyloid beta 40Placebo-controlled trialCerebrospinal fluid levelsEarly Alzheimer's diseaseAlzheimer's disease biomarkersDisease biomarkersPhosphorylation of tauClass III histoneSecondary outcomesAdverse eventsClinical characteristicsPrimary outcomeADCS-ADLStudy armsTreatment initiationCSF biomarkersADAS-Cog13Biomarker outcomesMean changeImpact of youth lay health workers on HIV service delivery in South Africa: A pragmatic cluster randomized trial of the Youth Health Africa program
Tollefson D, Dasgupta S, Setswe G, Reeves S, Charalambous S, Duerr A. Impact of youth lay health workers on HIV service delivery in South Africa: A pragmatic cluster randomized trial of the Youth Health Africa program. PLOS ONE 2023, 18: e0294719. PMID: 38033029, PMCID: PMC10688901, DOI: 10.1371/journal.pone.0294719.Peer-Reviewed Original ResearchConceptsHIV service deliveryHIV testingTreatment initiationIntervention facilitiesHealth workersYoung adultsAdolescents/young adultsProportion of patientsPragmatic clusterSecondary outcomesHIV positivityPrimary outcomeTreat analysisHIV servicesHIV programsHealth facilitiesHIVBaseline outcomesTrialsService deliveryNull trialsCareImmediate increaseOutcomesGreater improvement1483. Real-time Creation of HCV Treatment Cascades in Clinics to Improve HCV Treatment Rates Among Patients with HIV/HCV Co-infection
Wegener M, Brooks R, Nichols L, Villanueva M. 1483. Real-time Creation of HCV Treatment Cascades in Clinics to Improve HCV Treatment Rates Among Patients with HIV/HCV Co-infection. Open Forum Infectious Diseases 2023, 10: ofad500.1319. PMCID: PMC10677588, DOI: 10.1093/ofid/ofad500.1319.Peer-Reviewed Original ResearchHIV/HCVHCV treatmentHealth departmentsHIV/HCV Co-infectionSurveillance dataHCV Co-InfectionHCV PCR testingHCV surveillance dataHCV treatment cascadeHCV treatment ratesClinical care dataCounty Health DepartmentHCV careRyan WhiteSVR ratesHCV diagnosisTreatment cascadeTreatment initiationCo-InfectionHCV surveillanceTreatment eligibilityViral clearanceClinic levelCase conferencingMedical recordsReal-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment
Squires P, Puckett J, Ryland K, Kamal-Bahl S, Raut M, Doshi J, Huntington S. Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment. Blood 2023, 142: 2326. DOI: 10.1182/blood-2023-181024.Peer-Reviewed Original ResearchR mantle cell lymphomaHealthcare resource useLines of therapyMantle cell lymphomaMedian overall survivalOverall survivalTreatment initiationElderly patientsTyrosine kinase inhibitorsTreatment patternsPrior linesStandard chemotherapyU.S. patientsCell lymphomaReal-world treatment patternsRefractory mantle cell lymphomaBruton tyrosine kinase inhibitorsCause total costsFourth-line treatmentService Medicare coverageThird-line settingProgression-free survivalHalf of patientsHealthcare resource utilizationLarge unmet needReal-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
Huntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Jawaid D, Doshi J. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2316-2323. PMID: 37732602, DOI: 10.1080/10428194.2023.2255326.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaReal-world adherenceRefractory chronic lymphocytic leukemiaTyrosine kinase inhibitorsLymphocytic leukemiaB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsNovel oral agentsClinical trial dataOral agentsClinical characteristicsElderly patientsTreatment landscapeTreatment initiationReal-world findingsHigh adherenceMedicare beneficiariesLower discontinuationTrial dataDiscontinuationPatientsOlder adultsKinase inhibitorsAdherenceLeukemiaA user-centred implementation strategy for tuberculosis contact investigation in Uganda: protocol for a stepped-wedge, cluster-randomised trial
Katamba A, Gupta A, Turimumahoro P, Ochom E, Ggita J, Nakasendwa S, Nanziri L, Musinguzi J, Hennein R, Sekadde M, Hanrahan C, Byaruhanga R, Yoeli E, Turyahabwe S, Cattamanchi A, Dowdy D, Haberer J, Armstrong-Hough M, Kiwanuka N, Davis J. A user-centred implementation strategy for tuberculosis contact investigation in Uganda: protocol for a stepped-wedge, cluster-randomised trial. BMC Public Health 2023, 23: 1568. PMID: 37592314, PMCID: PMC10436440, DOI: 10.1186/s12889-023-16510-0.Peer-Reviewed Original ResearchConceptsContact investigationClinical effectiveness outcomesPrimary implementation outcomeTB contact investigationTB preventative therapyTB treatment initiationTimely TB diagnosisTrial registrationThe trialTuberculosis contact investigationCluster-randomised trialHigh-burden settingsImplementation-effectiveness trialEvidence-based interventionsUganda National CouncilWorld Health OrganizationProportion of contactsTB evaluationPeer-reviewed journalsMiddle-income countriesTreatment initiationTB diagnosisPreventative therapyUndiagnosed personsInfectious deathSputum samples
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply